Boston Scientific (BSX) is gaining traction in the emerging markets. New regulatory approvals bode well for the company’s growth. The stock carries a Zacks Rank #2 (Buy) currently. Boston Scientific continues to expand operations across different geographies outside the United States. In 2023, 41% of the company’s consolidated revenues came from international regions. Within its international regions, the company is putting additional efforts to expand its foothold in the emerging markets (defined as all co ...